Wanbury Limited

February 2006

1
Disclaimer
This presentation is made purely for information. We
have tried to give relevant information which we
believe will help in understanding the Company. The
viewers may use their own judgement and are advised
to make their own calculations before deciding on any
matter based on the information given herein. While
every care is taken to verify the accuracy of the
information given in this presentation, neither the
Company nor its officials would in any way be liable
for any action taken or not taken by the viewers or
the users of this presentation or for any claims, losses
etc. This is not a prospectus or document soliciting
investment in the Company

Wanbury Limited
Overview

3
 Our Vision

To become a global pharmaceutical company with

presence in Formulations and APIs .

a market capitalisation in excess of Rs.1000 cr

by March 2009

Wanbury Limited
Business Model

DOMESTIC
BULK FORMULATIONS
FORMULATIONS
BUSINESS OVERSEAS

Existing Existing Existing

Export Focus Focus on Domestic None
3 Plants Ethical Brands
New Product Intros.
Planned Planned Planned
Expansion Brand acquisitions European
Addl. plant Addition of division in Generics
medium term
Strategic
Associations
Wanbury Limited
Bulk Business

6
Snapshot
Worlds largest producer of Metformin

We sell to leading global generic players in regulated markets

Exporting to over 50 countries

Over 14 products ... Of these over 8 products for US and Europe

3 API facilities with 2 USFDA approved for multi product in Maharashtra

and AP

Over 24 products within 18 months and foray in contract manufacturing

Aggressive pitch of DMF Filings through a strengthened Research Base.

New R&D centre set up at Navi Mumbai for Process Research

Wanbury Limited
Key Customers
Apotex, Canada Mega Pharma, Mexico
Torr Pharma, USA Pure Pharma, Europe
Mylan, USA Salutos, Germany
Barr Laboratories, USA Wessex, UK
TEVA, Israel Tabuk, Saudi Arabia
Dexxon, Israel Pharmire, Sourth Korea
Pliva, USA Ranbaxy, India
Remedica, Cyprus Strides Arcolabs
Drageno Pharma, Germany Glenmark,India
Moleculus Mexico
Sun Pharma, India
Cadila Pharmaceuticals
Pfizer Alkem, India

Wanbury Limited
Product Portfolio
Metformin Gabapentene
Salsalate Int.

Existing Ibuprofen Tramadol

Glucosamine Amitryiptyline
Mefenamic Acid Promethazine

Sertraline
Paroxetine Hemihydrate
Introductions Carvedilol
Desloratidine
this year Losartan Potassium

Meloxicam Gliclazide
Fluvastatin
Pipeline

Pantaprazole
Glybenclamide Fluconazole
for 2007

Gabapentene
Clopidogrel
Hydrochlorthyzid
e

.a market size of over $ 2 Bn Wanbury Limited

 Product Pipeline
DMFs Available DMFs in Process Scale up Lab Stage New Products

Metformin HCl Losartan Potassium Carvedilol Pantaprazole Meloxicam

Ondansetron
Tramadol Hydrochloride (EDQM) Clopidogrel Hydrogen Methoxsalen Fluvastatin
Tramadol Hydrochloride( US) sulphate Risperidone Irbesartan Glybenclamide
Promethazine Hydrochloride Carvedilol Gliclazide
Venlafaxine
Sertraline Hydrochloride Diphenhydramine Fluconazole
Glimepiride
Amitriptyline Hydrochloride Hydrochloride Venlafaxine
Paroxetine Hydrochloride Glucosamine Sulfate Kcl

Metformin HCl DC grade 90% Glucosamine Sulfate NaCl

Metformin HCl DC grade 95%

Ibuprofen DC grade 90%
Glucosamine HCl
Ibuprofen
Mefenamic acid

Wanbury Limited
Our Research Strategy

Process Pharma
NDDS
Research Research

APIs for Regulated Development of Development of

markets ANDAs and novel platforms
/Emerging finished dosages for Specialty
markets for regulated Generics and IPR
and Contract markets
manufacturing
Time Frame Activity Scientists Outlay Expertise

Existing Existing set up 15 - APIs for Regulated Markets

Formulations and R&D
research
By March 05 New centre for Process 45 Rs. 5cr DMFs and Contract
Research Manufacturing
By Nov 06 New Centre for Research 70 Rs.15cr Formulations Research +
NDDS

Wanbury Limited
Our Research Strategy
NCE

NDDS

Development of novel platforms

for Speciality Generics and IPR

Pharma Research
Development of ANDAs and
finished dosages for regulated markets
Process Research
APIs for Regulated markets /Emerging markets
and Custom Synthesis
Wanbury Limited
Stage I- Process Research
Center
Area of Focus
Widening DMF pipeline for regulated markets (10 DMFs over 15 m)
New Product introductions for emerging markets
Intermediate manufacturing for innovators
Development for Contract Manufacturing
Widened coverage of therapeutic area
_ Custom synthesis
Research Set-up
Existing facilities to be strengthened and new Research Facility
being set up in Navi Mumbai
Team comprising 20 scientists with 4 PhDs in Organic Chemistry
Well equipped analytical Lab comprising HPLCs, GCs, FTIR, UV
Visible, Particle size analyser etc
Team expandable to 60 scientists over 24 months

Wanbury Limited
Stage II Research Center
Area of Focus
Development of Formulations
Dossier preparations and ANDA filings for regulated markets
Development of platforms for Novel Drug Delivery for Speciality
Generics
Clinical Research Capabilities for carrying out bio equivalence
studies

Research Set-up
New facility for a closed loop research lab to be set up close to
Mumbai/Pune
Full service Analytical Lab with NMR, HPLCs, GCs, FTIRs,
,XRD,DSC,GCMS,LCMS.
Lab Management Systems
Clinical Research capabilities starting with capabilities for bio
equivalence studies
Facilities for In vivo studies
Animal House for In vitro studies Wanbury Limited
Contract Manufacturing

Wanbury is well positioned to emerge as an

outsourcing partner of choice due to our quest for
quality, desire for innovation, a highly efficient
supply chain management and optimal utilization of
capacities.

Wanbury is in an unique position to offer a single

point of contract for R&D, process development
and production. Availability of dedicated, adequately
trained and highly qualified manpower in R&D ,
production and QA/RA.

Wanbury Limited
Custom Synthesis
Custom synthesis

Already carrying out synthesis for European

customers

Expanding team of scientific officers to procure

business

New systems to be incorporated in the R&D to

strengthen IPR protection and facilitate business

Wanbury Limited
Reaction Capabilities
In addition to general reactions we are specialised in the following
Azidation
Bromination
Reactions involving Butyl Lithium
Cyanation
Chiral chemistry
Griganard
Sodium metal reactions
Metal hydride reductions
Optical Resolution
High Pressure Reactions
Hydrogenation
High Temperature Reactions (250C)
High Vacuum Distillations
Low Temperature Reactions (-80C)

Wanbury Limited
Formulation Business

18
Our Formulation
Business
Founded in 1865 by Dr. George Wander in Berne, Switzerland

Wander has been in the Indian market since late forties with its
cold and nutrition products originally a subsidiary of Sandoz

Now a Wanbury division with 310 professionals, 16 brands, 24

Distributors and about 1200 stockists across the country.

Independent Formulation Research and Development Centre at

Chembur recognised by Govt. of India

Strong focus on Pediatrics, Gynecology and Orthopedics

Growth through niche neutraceuticals led lifestyle segment

Wanbury Limited
Brands
Doctor Segment Brands
Doctor Segment Brands
C-Pink
C-Pink
Coriminic
Pediatrics Coriminic
Pediatrics Zeva
Zeva
Nurture
Nurture
SetCal
SetCal
Gemron
Gynecologists Gemron
Gynecologists Cemax-O
Cemax-O
Cefcare
Cefcare
Oftek
Oftek
Ofgyl
Orthopedics Ofgyl
Orthopedics Nock -2
Nock -2
Adtrol
Adtrol
Clamist
Clamist
Senasof
Consulting Physicians Senasof
Consulting Physicians
GPs
GPs
Wanbury Limited
Growth Strategy

21
Growth Strategy
LEVERAGE ON .
Existing Satisfied Customers

Strong Marketing Skills

In-house technical
Global competence
Generics
Contract
Manufacturing In-house Research expertise
Strategic
Alliance
Product Experience in managing and
Introductions Life Style
Division building US FDA approved
Acquisitions
plants
Expansion Improve PCPM

4 Years
Wanbury Limited
Management

23
Board of Directors

Mr. K Chandran ..ED

Mr. K.R.N. Moorthy ..ED
Mr. N. K. Puri ..Independent
Dr. P. L. Tiwari ..Independent
Mr. A. Bongirwar ..Independent
Mr. S. Bhattacharya ..Nominee(EXIM)

Wanbury Limited
Advisory Board

Mr. K. R. N. Moorthy is supported by

an advisory board:

Mr. S. Balsekhar,
Ex-Chairman Roussel Pharmaceutical

Dr. Indira Parekh,

Dean IIM Ahmedabad

Group Directors

Wanbury Limited
Human Resources

Wanbury Limited
 Key Personnel
BOARD of DIRECTORS
ADVISORY BOARD

K R N MOORTHY ASHOK SHINKAR

ED & President APIs/Formulations Director C F (M&A)

S R Jagannathan Dr S Samant S Jayaram

Sr. VP Operations V P Marketing V P Legal

M.K. PADMANABHAN P. Gupta

Dr. Pulla Rao
National Sales Manager Company Sec.
Head QA and Regulatory

Vijayan Nair V S Ayare Mahesh Kolatkar

GM Finance R&D AGM IT

Raman Iyer Kurush Dubash

GM Marketing Head Training

Dr Shankar Surina Iyer

GM R&D DGM HR
Wanbury Limited
Management Key personnel

Wanbury Limited
 HR Thrust .. Focus Areas

Talent Acquisition Selection Techniques

Team Alignment & Rationalization
Measuring Performance & Assessing Potential
Compensation Benchmarking
Capability Building and Leadership Development
Career Development & Succession Planning
Create Think Tank ~ Innovative Practices
Communication Openness Transparency - Speed
System Orientation

Building Human Capital .. For Superior & Competitive Results

Wanbury Limited
 Wanburys VALUES

Respect for People

Innovation
Sense of Urgency
Result Focus
Leadership
Team Work
Customer Focus

Wanbury Limited
 Mission statement

We at Wanbury, want to make a company that employees are proud of

and committed to, where every employee has an opportunity to
contribute, learn, grow and advance on merit.
We are dedicated in improving quality of our employees by continuously
providing high quality training and development.
We will continue to establish a business model, which is predictable,
sustainable, growth oriented and profitable.
We will always worship exceptional and superior performance. We will
continuously challenge status-quo / maintenance and simultaneously
encourage and recognize stretch and growth.
We will work hard not only to satisfy but delight our customers (both
internal and external).
We will strive to make Wanbury one of the preferred employers.

Wanbury Limited
Thank You

32